Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN stock opened at $2.24 on Friday. Evogene has a 52 week low of $2.02 and a 52 week high of $10.40. The company’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $4.93.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). The company had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.